Form 4: GoodRx Director Bezdek Receives Equity Awards

GoodRx Holdings, Inc. Director Trevor Bezdek was granted restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Trevor Bezdek, a Director of GoodRx Holdings, Inc. (GDRX), acquired 33,530 shares of Class A Common Stock in the form of restricted stock units (RSUs) on November 2, 2025.
• These 33,530 RSUs vest in full on the earlier of June 3, 2026, or the date of the 2026 Annual Meeting of Stockholders, contingent on continued service.
• Bezdek also acquired 104,925 derivative restricted stock units on November 2, 2025.
• These 104,925 derivative RSUs vest as to one-third of the shares on each of the first three anniversaries of the grant date, commencing November 2, 2026, subject to continued service.
• Following these transactions, Bezdek directly beneficially owns 160,082 shares of Class A Common Stock and 104,925 derivative restricted stock units.
• He also indirectly holds 2,632,721 shares of Class A Common Stock through the TB 2024-2 GRAT, where he is the sole trustee and annuitant.
• An additional 2,632,721 shares are held indirectly by the JB 2024-2 GRAT, for which his spouse, Jana Bezdek, is the sole trustee and annuitant; Bezdek disclaims beneficial ownership of these shares.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation in the form of restricted stock units granted to a director. This is a standard practice to incentivize and retain key personnel, aligning their interests with long-term shareholder value. It does not indicate any significant operational or financial changes.

Positives

• The acquisition of restricted stock units aligns the director's long-term interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• Equity compensation is a standard practice to incentivize key personnel and retain talent.

Risks

• The vesting of the restricted stock units is contingent upon continued service through the applicable vesting dates, meaning the director must remain employed or serving to receive the shares.

Future Outlook

NA

Industry Context

Equity compensation, particularly through restricted stock units, is a common practice across various industries to attract, retain, and incentivize directors and executives, aligning their interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice across publicly traded companies, including those in the healthcare technology sector like GoodRx.
• Vesting schedules tied to continued service, such as the full vesting on a specific future date or annual vesting over several years, are typical for RSU grants, comparable to practices at companies like Teladoc Health (TDOC) or Amwell (AMWL) which also utilize equity awards for their leadership.
• The grant price of $0 for RSUs is standard, as these represent a right to receive shares upon vesting, not a purchase.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 2,632,721 shares of Class A Common Stock through the TB 2024-2 GRAT, where Trevor Bezdek serves as sole trustee and annuitant.
• Indirect beneficial ownership of 2,632,721 shares of Class A Common Stock through the JB 2024-2 GRAT, where Jana Bezdek (spouse of Trevor Bezdek) serves as sole trustee and annuitant. Trevor Bezdek disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially encouraging decisions that benefit stock performance.
• Employees: The grants demonstrate the company's commitment to equity-based compensation for its leadership, which can be a positive signal for employee retention and motivation.

Next Steps

• Continued service by Trevor Bezdek to meet vesting conditions for the restricted stock units.
• Vesting of 33,530 RSUs on the earlier of June 3, 2026, or the 2026 Annual Meeting of Stockholders.
• Annual vesting of 104,925 RSUs over three years, commencing November 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice and does not provide new information that would fundamentally alter the investment thesis for GoodRx Holdings, Inc. It aligns the director's interests with long-term shareholder value but does not indicate any significant operational changes or financial performance updates that would warrant a change in investment recommendation.

Keywords

GoodRx Holdings, GDRX, Trevor Bezdek, Form 4, SEC filing, restricted stock units, RSU, equity compensation, director, beneficial ownership, GRAT